Oliver Manzke

2.4k total citations · 1 hit paper
36 papers, 1.9k citations indexed

About

Oliver Manzke is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Pathology and Forensic Medicine. According to data from OpenAlex, Oliver Manzke has authored 36 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 18 papers in Radiology, Nuclear Medicine and Imaging and 17 papers in Pathology and Forensic Medicine. Recurrent topics in Oliver Manzke's work include Monoclonal and Polyclonal Antibodies Research (18 papers), Lymphoma Diagnosis and Treatment (17 papers) and CAR-T cell therapy research (15 papers). Oliver Manzke is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (18 papers), Lymphoma Diagnosis and Treatment (17 papers) and CAR-T cell therapy research (15 papers). Oliver Manzke collaborates with scholars based in Germany, United States and United Kingdom. Oliver Manzke's co-authors include Volker Diehl, Andreas Engert, Heribert Bohlen, Mark A. Jensen, U. Winkler, H. Schulz, Hans Tesch, Bernd K. Fleischmann, Eugen Kolossov and Olaf Christensen and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Cell Biology and Blood.

In The Last Decade

Oliver Manzke

35 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8)

1999 516 citations U. Winkler, Mark A. Jensen et al. Blood profile →

Peers

Countries citing papers authored by Oliver Manzke

Since Specialization

Citations

This map shows the geographic impact of Oliver Manzke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Oliver Manzke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Oliver Manzke more than expected).

Fields of papers citing papers by Oliver Manzke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Oliver Manzke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Oliver Manzke. The network helps show where Oliver Manzke may publish in the future.

Co-authorship network of co-authors of Oliver Manzke

This figure shows the co-authorship network connecting the top 25 collaborators of Oliver Manzke. A scholar is included among the top collaborators of Oliver Manzke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Oliver Manzke. Oliver Manzke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial 2021 ·International Journal of Hematology ·Grzegorz S. Nowakowski, Wolfgang Willenbacher, Richard Greil, Thomas Stauffer Larsen, Krish Patel, Ulrich Jäger, Robert Manges, Lorenz Trümper, Hele Everaus, Nagesh Kalakonda, Peter de Nully Brown, Judit Jørgensen, David Cunningham, (unknown), Brian A. Fox, (unknown), Nurgul Kilavuz, (unknown), Oliver Manzke, Javier Muñoz	17
2	Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R²-CHOP in subjects with previously untreated, high-risk DLBCL. 2019 ·Journal of Clinical Oncology ·Grzegorz S. Nowakowski, Wolfgang Willenbacher, Richard Greil, Thomas Stauffer Larsen, Krish Patel, Ulrich Jäger, Robert Manges, Lorenz Trümper, Corinne Haïoun, Hele Everaus, Nagesh Kalakonda, Jeanna Knoble, Peter de Nully Brown, (unknown), David Cunningham, (unknown), (unknown), Oliver Manzke, Javier Muñoz	10
3	Phase II study of durvalumab (anti-PD-L1 antibody) in combination with R-CHOP or lenalidomide plus R-CHOP in previously untreated, high-risk diffuse large B-cell lymphoma. 2017 ·Journal of Clinical Oncology ·Grzegorz S. Nowakowski, Nagesh Kalakonda, Lorenz Truemper, Hele Everaus, Pierre Fustier, Jonathan Jaeger, Oliver Manzke, Ulrich Jäger, (unknown)	2
4	Dendritic cells are significantly reduced in non-Hodgkin's lymphoma and express less CCR7 and CD62L 2006 ·Leukemia & lymphoma ·Francesca Fiore, Michael S. von Bergwelt‐Baildon, Uta Drebber, Marc Beyer, Alexey Popov, Oliver Manzke, Claudia Wickenhauser, S. Baldus, Joachim L. Schultze	24
5	Identification and characterization of embryonic stem cell‐derived pacemaker and atrial cardiomyocytes 2005 ·The FASEB Journal ·Eugen Kolossov, Zhongju Lu, (unknown), Natig Gassanov, Yaqi Duan, Heinrich Sauer, Oliver Manzke, Wilhelm Bloch, Heribert Bohlen, Jürgen Hescheler, Bernd K. Fleischmann	88
6	Modulation of MUC1 and blood group antigen expression in gastric adenocarcinoma cells by cytokines 2003 ·Cytokine ·(unknown), Peter Schirmacher, Oliver Manzke, Franz‐Georg Hanisch, Hans Peter Dienes, Stephan Baldus	6
7	Intraventricular and Intravenous Treatment of a Patient with Refractory Primary CNS Lymphoma using Rituximab 2002 ·Journal of Neuro-Oncology ·Hendrik Pels, H. Schulz, Oliver Manzke, (unknown), Aron D. Thall, Andreas Engert	54
8	Locoregional treatment of low-grade B-cell lymphoma with CD3�CD19 bispecific antibodies and CD28 costimulation: II. Assessment of cellular immune responses 2001 ·International Journal of Cancer ·Oliver Manzke, Hans Tesch, Johann Lorenzen, Volker Diehl, Heribert Bohlen	22
9	Immunotherapeutic strategies in neuroblastoma: Antitumoral activity of deglycosylated ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies 2001 ·Medical and Pediatric Oncology ·Oliver Manzke, (unknown), (unknown), Volker Diehl, Heribert Bohlen, Frank Berthold	18
10	Male gonadal dysfunction in patients with Hodgkin’s disease prior to treatment 2001 ·Annals of Oncology ·U. Rueffer, Kai Breuer, Andreas Josting, B. Lathan, M. Sieber, Oliver Manzke, (unknown), Hans Tesch, Henning Bredenfeld, P. Koch, Hiltrud Nisters-Backes, Jennifer Moriatis Wolf, Andreas Engert, Volker Diehl	131
11	Locoregional treatment of low-grade B-cell lymphoma with CD3�CD19 bispecific antibodies and CD28 costimulation: I. Clinical phase I evaluation 2001 ·International Journal of Cancer ·Oliver Manzke, Hans Tesch, (unknown), (unknown), K. Lackner, Axel Goßmann, Volker Diehl, Heribert Bohlen	20
12	Vaccination of multiple myeloma patients with idiotype‐pulsed dendritic cells: immunological and clinical aspects 2000 ·British Journal of Haematology ·(unknown), Olaf Christensen, Oliver Manzke, Hans Tesch, Jürgen Wolf, B. Emmerich, (unknown), Volker Diehl, Heribert Bohlen	168
13	Treatment of patients with malignant lymphomas with monoclonal antibodies 2000 ·Bone Marrow Transplantation ·Hans Tesch, Andreas Engert, Oliver Manzke, Volker Diehl, Heribert Bohlen	4
14	CD3� anti-nitrophenyl bispecific diabodies: Universal immunotherapeutic tools for retargeting T cells to tumors 1999 ·International Journal of Cancer ·Oliver Manzke, Kevin Fitzgerald, Philipp Holliger, (unknown), (unknown), Bernd K. Fleischmann, Juergen Hescheler, Qinghua Liu, Kevin S. Johnson, Volker Diehl, Hennie R. Hoogenboom, Heribert Bohlen	12
15	CD3xCD19 bispecific antibodies and CD28 bivalent antibodies enhance T-cell reactivity against autologous leukemic cells in pediatric B-ALL bone marrow 1999 ·International Journal of Cancer ·Oliver Manzke, Frank Berthold, (unknown), Hans Tesch, Volker Diehl, Heribert Bohlen	18
16	Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8) breakdown → 1999 ·Blood ·U. Winkler, Mark A. Jensen, Oliver Manzke, H. Schulz, Volker Diehl, Andreas Engert	516
17	Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) 1998 ·Annals of Hematology ·Mark A. Jensen, U. Winkler, Oliver Manzke, Volker Diehl, Andreas Engert	81
18	CD3×CD19 bispecific antibodies and CD28 costimulation for locoregional treatment of low-malignancy non-Hodgkin's lymphoma 1997 ·Cancer Immunology Immunotherapy ·Oliver Manzke, (unknown), Hans Tesch, Volker Diehl, Heribert Bohlen	17
19	Single-step purification of bispecific monoclonal antibodies for immunotherapeutic use by hydrophobic interaction chromatography 1997 ·Journal of Immunological Methods ·Oliver Manzke, Hans Tesch, Volker Diehl, Heribert Bohlen	45
20	Differentiation of cytotoxicity using target cells labelled with europium and samarium by electroporation 1994 ·Journal of Immunological Methods ·Heribert Bohlen, Oliver Manzke, Andreas Engert, (unknown), (unknown), Volker Diehl, Hans Tesch	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact